Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.

Beatriz Collado, María J. Carmena, Manuel Sánchez-Chapado, Antonio Ruíz-Villaespesa, Ana M. Bajo, Ana B. Fernández-Martínez, Jozsef L. Varga, Andrew V Schally, Juan C. Prieto

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Vasoactive intestinal peptide (VIP) functions as a mitogenic agent in the human prostate gland acting by autocrine/paracrine mechanisms. Here we extend knowledge on the VIP system (expression of VIP and VIP receptors, functionality of VIP receptors) at this level by analyzing the differences between human normal prostate and prostate carcinoma specimens. RT-PCR showed the expression of mRNA for VIP in normal and malignant tissues, whereas VIP levels, as measured by enzyme immuno-analysis, were about two times higher in adenocarcinoma samples. Real-time RT-PCR indicated a minor expression of VPAC2 receptors in the prostate gland, as well as the overexpression of VPAC1 and PAC1 receptors in malignant tissue specimens. Radio-labeled binding experiments with [125I]VIP showed an increased number of VIP binding sites (2.5 times for the high- and 1.7 times for the low-affinity sites) during malignant transformation, whereas the affinity values were unaffected. The receptors were functional in control and cancer tissues as shown by the ability of increasing VIP doses to stimulate adenylate cyclase activity. Interestingly, JV-1-53 (a GHRH-related peptide analog) (at 0.1 microM) behaved as a potent VIP antagonist since it inhibited by 60% the maximal VIP effect upon the enzyme activity. The results further explain the mechanisms of the autocrine/paracrine actions of VIP in human prostate and prostatic carcinoma through the observation of differences between healthy tissue and malignant transformation. Moreover, present data support the potential usefulness of VIP and/or synthetic peptide analogs for diagnostic or radiotherapeutic purposes as well as for long-term peptide therapy in this malignancy.

Original languageEnglish
Pages (from-to)1629-1635
Number of pages7
JournalInternational Journal of Oncology
Volume26
Issue number6
StatePublished - Jun 1 2005
Externally publishedYes

Fingerprint

Vasoactive Intestinal Peptide Receptors
Growth Hormone-Releasing Hormone
Vasoactive Intestinal Peptide
Prostatic Neoplasms
Prostate
Receptors, Vasoactive Intestinal Peptide, Type II
Receptors, Vasoactive Intestinal Polypeptide, Type I
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
Carcinoma
Peptides
Enzymes
Radio
Adenylyl Cyclases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Collado, B., Carmena, M. J., Sánchez-Chapado, M., Ruíz-Villaespesa, A., Bajo, A. M., Fernández-Martínez, A. B., ... Prieto, J. C. (2005). Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. International Journal of Oncology, 26(6), 1629-1635.

Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer : antagonistic action of a growth-hormone-releasing hormone analog. / Collado, Beatriz; Carmena, María J.; Sánchez-Chapado, Manuel; Ruíz-Villaespesa, Antonio; Bajo, Ana M.; Fernández-Martínez, Ana B.; Varga, Jozsef L.; Schally, Andrew V; Prieto, Juan C.

In: International Journal of Oncology, Vol. 26, No. 6, 01.06.2005, p. 1629-1635.

Research output: Contribution to journalArticle

Collado, B, Carmena, MJ, Sánchez-Chapado, M, Ruíz-Villaespesa, A, Bajo, AM, Fernández-Martínez, AB, Varga, JL, Schally, AV & Prieto, JC 2005, 'Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.', International Journal of Oncology, vol. 26, no. 6, pp. 1629-1635.
Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB et al. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. International Journal of Oncology. 2005 Jun 1;26(6):1629-1635.
Collado, Beatriz ; Carmena, María J. ; Sánchez-Chapado, Manuel ; Ruíz-Villaespesa, Antonio ; Bajo, Ana M. ; Fernández-Martínez, Ana B. ; Varga, Jozsef L. ; Schally, Andrew V ; Prieto, Juan C. / Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer : antagonistic action of a growth-hormone-releasing hormone analog. In: International Journal of Oncology. 2005 ; Vol. 26, No. 6. pp. 1629-1635.
@article{fd5aa9ad8d34405c80d7666c6fe54e12,
title = "Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.",
abstract = "Vasoactive intestinal peptide (VIP) functions as a mitogenic agent in the human prostate gland acting by autocrine/paracrine mechanisms. Here we extend knowledge on the VIP system (expression of VIP and VIP receptors, functionality of VIP receptors) at this level by analyzing the differences between human normal prostate and prostate carcinoma specimens. RT-PCR showed the expression of mRNA for VIP in normal and malignant tissues, whereas VIP levels, as measured by enzyme immuno-analysis, were about two times higher in adenocarcinoma samples. Real-time RT-PCR indicated a minor expression of VPAC2 receptors in the prostate gland, as well as the overexpression of VPAC1 and PAC1 receptors in malignant tissue specimens. Radio-labeled binding experiments with [125I]VIP showed an increased number of VIP binding sites (2.5 times for the high- and 1.7 times for the low-affinity sites) during malignant transformation, whereas the affinity values were unaffected. The receptors were functional in control and cancer tissues as shown by the ability of increasing VIP doses to stimulate adenylate cyclase activity. Interestingly, JV-1-53 (a GHRH-related peptide analog) (at 0.1 microM) behaved as a potent VIP antagonist since it inhibited by 60{\%} the maximal VIP effect upon the enzyme activity. The results further explain the mechanisms of the autocrine/paracrine actions of VIP in human prostate and prostatic carcinoma through the observation of differences between healthy tissue and malignant transformation. Moreover, present data support the potential usefulness of VIP and/or synthetic peptide analogs for diagnostic or radiotherapeutic purposes as well as for long-term peptide therapy in this malignancy.",
author = "Beatriz Collado and Carmena, {Mar{\'i}a J.} and Manuel S{\'a}nchez-Chapado and Antonio Ru{\'i}z-Villaespesa and Bajo, {Ana M.} and Fern{\'a}ndez-Mart{\'i}nez, {Ana B.} and Varga, {Jozsef L.} and Schally, {Andrew V} and Prieto, {Juan C.}",
year = "2005",
month = "6",
day = "1",
language = "English",
volume = "26",
pages = "1629--1635",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer

T2 - antagonistic action of a growth-hormone-releasing hormone analog.

AU - Collado, Beatriz

AU - Carmena, María J.

AU - Sánchez-Chapado, Manuel

AU - Ruíz-Villaespesa, Antonio

AU - Bajo, Ana M.

AU - Fernández-Martínez, Ana B.

AU - Varga, Jozsef L.

AU - Schally, Andrew V

AU - Prieto, Juan C.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Vasoactive intestinal peptide (VIP) functions as a mitogenic agent in the human prostate gland acting by autocrine/paracrine mechanisms. Here we extend knowledge on the VIP system (expression of VIP and VIP receptors, functionality of VIP receptors) at this level by analyzing the differences between human normal prostate and prostate carcinoma specimens. RT-PCR showed the expression of mRNA for VIP in normal and malignant tissues, whereas VIP levels, as measured by enzyme immuno-analysis, were about two times higher in adenocarcinoma samples. Real-time RT-PCR indicated a minor expression of VPAC2 receptors in the prostate gland, as well as the overexpression of VPAC1 and PAC1 receptors in malignant tissue specimens. Radio-labeled binding experiments with [125I]VIP showed an increased number of VIP binding sites (2.5 times for the high- and 1.7 times for the low-affinity sites) during malignant transformation, whereas the affinity values were unaffected. The receptors were functional in control and cancer tissues as shown by the ability of increasing VIP doses to stimulate adenylate cyclase activity. Interestingly, JV-1-53 (a GHRH-related peptide analog) (at 0.1 microM) behaved as a potent VIP antagonist since it inhibited by 60% the maximal VIP effect upon the enzyme activity. The results further explain the mechanisms of the autocrine/paracrine actions of VIP in human prostate and prostatic carcinoma through the observation of differences between healthy tissue and malignant transformation. Moreover, present data support the potential usefulness of VIP and/or synthetic peptide analogs for diagnostic or radiotherapeutic purposes as well as for long-term peptide therapy in this malignancy.

AB - Vasoactive intestinal peptide (VIP) functions as a mitogenic agent in the human prostate gland acting by autocrine/paracrine mechanisms. Here we extend knowledge on the VIP system (expression of VIP and VIP receptors, functionality of VIP receptors) at this level by analyzing the differences between human normal prostate and prostate carcinoma specimens. RT-PCR showed the expression of mRNA for VIP in normal and malignant tissues, whereas VIP levels, as measured by enzyme immuno-analysis, were about two times higher in adenocarcinoma samples. Real-time RT-PCR indicated a minor expression of VPAC2 receptors in the prostate gland, as well as the overexpression of VPAC1 and PAC1 receptors in malignant tissue specimens. Radio-labeled binding experiments with [125I]VIP showed an increased number of VIP binding sites (2.5 times for the high- and 1.7 times for the low-affinity sites) during malignant transformation, whereas the affinity values were unaffected. The receptors were functional in control and cancer tissues as shown by the ability of increasing VIP doses to stimulate adenylate cyclase activity. Interestingly, JV-1-53 (a GHRH-related peptide analog) (at 0.1 microM) behaved as a potent VIP antagonist since it inhibited by 60% the maximal VIP effect upon the enzyme activity. The results further explain the mechanisms of the autocrine/paracrine actions of VIP in human prostate and prostatic carcinoma through the observation of differences between healthy tissue and malignant transformation. Moreover, present data support the potential usefulness of VIP and/or synthetic peptide analogs for diagnostic or radiotherapeutic purposes as well as for long-term peptide therapy in this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=22344451194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344451194&partnerID=8YFLogxK

M3 - Article

C2 - 15870879

AN - SCOPUS:22344451194

VL - 26

SP - 1629

EP - 1635

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -